AKT1 and prostate carcinoma: AZD5363, on the other hand, is an inhibitor of AKT isoforms 1, 2 and 3 which has synergy with enzalutamide in preclinical models of enzalutamide-resistant prostate cancer and docetaxel in CRPC [106].